| [1] |
Kishore SP，Blank E，Heller DJ，et al.Modernizing the World Health Organization list of essential medicines for preventing and controlling cardiovascular diseases[J].J Am Coll Cardiol，2018，71（5）：564-574.
|
| [2] |
周阔，吕树铮，宋现涛，等.药物洗脱支架置入术后再发支架内血栓患者的危险因素分析[J].心肺血管病杂志，2018，37（5）：402-405.
|
| [3] |
Sukiennik A，Kasprzak M，Mazurek W，et al.High-risk percutaneous coronary intervention with impella CP hemodynamic support.A case series and method presentation[J].Postepy Kardiol Interwencyjnej，2017，13（1）：67-71.
|
| [4] |
Borovac JA，D′Amario D，Vergallo R，et al.Neoatherosclerosis after drug-eluting stent implantation：a novel clinical and therapeutic challenge[J].Eur Heart J Cardiovasc Pharmacother，2019，5（2）：105-116.
|
| [5] |
Stuijfzand WJ，Biesbroek PS，Raijmakers PG，et al.Effects of successful percutaneous coronary intervention of chronic total occlusions on myocardial perfusion and left ventricular function[J].Euro Intervention，2017，13（3）：345-354.
|
| [6] |
Mons U，Müezzinler A，Gellert C，et al.Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults：meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium[J].BMJ，2015，350：h1551.
|
| [15] |
胡波.CYP2C19 基因多态性对不同种族人群服用氯吡格雷疗效的影响[A].中华医学会，中华医学会神经病学分会.中国脑血管病大会2014 论文汇编[C].长沙：中华医学会，2014：1.
|
| [18] |
刘滴，吴辉，杨俊，等.替格瑞洛对比氯吡格雷治疗东亚ACS 患者有效性和安全性的Meta 分析[J].中国药房，2020，31（10）：1260-1265.
|
| [7] |
Balakumar P，Kaur J.Is nicotine a key player or spectator in the induction and progression of cardiovascular disorders?[J].Pharmacol Res，2009，60（5）：361-368.
|
| [8] |
Yagi H，Komukai K，Hashimoto K，et al.Difference in risk factors betweenacute coronary syndrome and stable angina pectoris in the Japanese：Smoking asa crucial risk factor of acute coronary syndrome[J].J Cardiol，2010，55（3）：345-353.
|
| [9] |
Pleva L，Kukla P，Hlinomaz O.Treament of coronary in-stent restenosis：a systematic review[J].J Geriatr Cardiol，2018，15（2）：173-184.
|
| [10] |
Iakovou I，Schmidt T，Bonizzoni E，et al.Incidence predictors and outcomeof thrombosis after successful implantation of drug-eluting stents[J].JAMA，2005，293（10）：2126-2130.
|
| [11] |
Hulot JS，Bura A，Villard E，et al.Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects[J].Blood，2006，108（7）：2244-2247.
|
| [12] |
Mega JL，Close SL，Wiviott SD，et al.Cytochrome p-450 polymorphisms and response to clopidogrel[J].N Engl J Med，2009，360（4）：354-362.
|
| [13] |
Bouman HJ，Schm ig E，van Werkum JW，et al.Paraoxonase-1 is a major determinant of clopidogrel efficacy[J].Nat Med，2011，17（9）：1153.
|
| [14] |
Simon T，Verstuyft C，Mary-Krause M，et al.Genetic determinants of response to clopidogrel and cardiovascular events[J].N Engl J Med，2009，360（4）：363-375.
|
| [16] |
Gremmel T，Steiner S，Seidinger D，et al.Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition[J].Heart，2010，96（3）：186-189.
|
| [17] |
Chen Y，Dong W，Wan Z，et al.Ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome：a pharmacodynamic analysis[J].Int J Cardiol，2015，201：545-546.
|
